Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NTSR1 | P30989 | 2/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.46 |
| ▸ | POLB | P06746 | 2/20 | 0.46 |
| ▸ | PDE4A | P27815 | 3/20 | 0.44 |
| ▸ | PDE4D | Q08499 | 3/20 | 0.44 |
| ▸ | PDE3B | Q13370 | 3/20 | 0.41 |
| ▸ | PDE3A | Q14432 | 3/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.40 |
| ▸ | ELANE | P08246 | 1/20 | 0.40 |
| ▸ | HTT | P42858 | 1/20 | 0.40 |
| ▸ | PGK1 | P00558 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.38 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.38 |
| ▸ | GAA | P10253 | 2/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.37 |
| ▸ | GLA | P06280 | 1/20 | 0.37 |
| ▸ | SMARCA2 | P51531 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24067374 | 0.87 | NTSR1 (0.42) | NTSR1KDM4EPOLBPDE4APDE4D | |
| SCHEMBL24067370 | 0.79 | ALDH1A1 (0.40) | KDM4EPOLBPDE4APDE4DALDH1A1 | |
| SCHEMBL24015771 | 0.79 | NTSR1 (0.50) | NTSR1KDM4EPDE4APDE4DPDE3B | |
| SCHEMBL25671167 | 0.79 | PDE4A (0.51) | KDM4EPOLBPDE4APDE4DPDE3B | |
| SCHEMBL25680896 | 0.79 | NTSR1 (0.50) | NTSR1KDM4EPOLBPDE4APDE4D | |
| SCHEMBL25670599 | 0.79 | KDM4E (0.32) | KDM4ESMN1; SMN2 | |
| SCHEMBL15819368 | 0.78 | ENPP1 (0.51) | NTSR1KDM4EPDE4APDE4DPDE3B | |
| SCHEMBL20813450 | 0.78 | NTSR1 (0.49) | NTSR1KDM4EPOLBPDE4APDE4D | |
| SCHEMBL14090663 | 0.78 | SMN1; SMN2 (0.51) | KDM4EPOLBPDE3BPDE3AALDH1A1 | |
| SCHEMBL29589930 | 0.78 | ENPP1 (0.51) | NTSR1KDM4EPDE4APDE4DPDE3B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230277570-A1 | ENPP1 Inhibitors and Their Use for the Treatment of Cancer | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY | 2023-09-07 | — | — | US | disclosed |
| US-20230277570-A1 | ENPP1 Inhibitors and Their Use for the Treatment of Cancer | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY | 2023-09-07 | — | — | US | disclosed |
| US-11707471-B2 | ENPP1 inhibitors and their use for the treatment of cancer | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (US) | 2023-07-25 | — | — | US | disclosed |
| US-11701371-B2 | ENPP1 inhibitors and their use for the treatment of cancer | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (US) | 2023-07-18 | — | — | US | disclosed |
| US-20230190927-A1 | ENPP1 INHIBITORS AND METHODS OF MODULATING IMMUNE RESPONSE | CYANA THERAPEUTICS LLC | 2023-06-22 | — | — | US | disclosed |
| US-20210369747-A1 | ENPP1 Inhibitors and Their Use for the Treatment of Cancer | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY | 2021-12-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11701371-B2 | ENPP1 inhibitors and their use for the treatment of cancer | ENPP1, ENPP3, ENTPD1 | NTSR1 3545/4885KDM4E 3368/4885POLB 699/4885 |
| US-20210369747-A1 | ENPP1 Inhibitors and Their Use for the Treatment of Cancer | ENPP1, ENPP3, ENTPD1 | NTSR1 3545/4885KDM4E 3368/4885POLB 699/4885 |
| US-20230190927-A1 | ENPP1 INHIBITORS AND METHODS OF MODULATING IMMUNE RESPONSE | ENPP1, STING1, ENPP3 | NTSR1 3249/4885KDM4E 3971/4885POLB 1829/4885 |
| US-11707471-B2 | ENPP1 inhibitors and their use for the treatment of cancer | ENPP1, ENPP3, ENTPD1 | NTSR1 3545/4885KDM4E 3368/4885POLB 699/4885 |
| US-20230277570-A1 | ENPP1 Inhibitors and Their Use for the Treatment of Cancer | ENPP1, ENPP3, ENTPD1 | NTSR1 3545/4885KDM4E 3368/4885POLB 699/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.